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Aims Anti-Apolipoprotein A-1 auto-antibodies (anti-ApoA-1 IgG) represent an emerging prognostic cardiovascular marker
in patients with myocardial infarction or autoimmune diseases associated with high cardiovascular risk. The potential
relationship between anti-ApoA-1 IgG and plaque vulnerability remains elusive. Thus, we aimed to investigate the role
of anti-ApoA-1 IgG in plaque vulnerability.
Methods
and results
Potential relationship between anti-ApoA-1 IgG and features of cardiovascular vulnerability was explored both in vivo
and in vitro. In vivo, we investigated anti-ApoA-1 IgG in patients with severe carotid stenosis (n ¼ 102) and in
ApoE2/2 mice infused with polyclonal anti-ApoA-1 IgG. In vitro, anti-ApoA-1 IgG effects were assessed on
human primary macrophages, monocytes, and neutrophils. Intraplaque collagen was decreased, while neutrophil
and matrix metalloprotease (MMP)-9 content were increased in anti-ApoA-1 IgG-positive patients and anti-ApoA-
1 IgG-treated mice when compared with corresponding controls. In mouse aortic roots (but not in abdominal
aortas), treatment with anti-ApoA-1 IgG was associated with increased lesion size when compared with controls.
In humans, serum anti-ApoA-1 IgG levels positively correlated with intraplaque macrophage, neutrophil, and
MMP-9 content, and inversely with collagen. In vitro, anti-ApoA-1 IgG increased macrophage release of CCL2,
CXCL8, and MMP-9, as well as neutrophil migration towards TNF-a or CXCL8.
Conclusion These results suggest that anti-ApoA-1 IgG might be associated with increased atherosclerotic plaque vulnerability in
humans and mice.
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Introduction
During the past decades, the concept of global ‘cardiovascular vul-
nerability’ opened new perspective in cardiovascular prevention.1,2
The possible identification of serum markers reflecting intraplaque
vulnerability (easier to be measured than intraplaque parameters)
could be of particular importance in both primary and secondary
prevention of cardiovascular diseases. Simultaneously, it was
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established that atherosclerosis is not only a collection of choles-
terol, complicated by smooth muscle cell proliferation, but also a
chronic inflammatory disease, involving both innate and adaptive
immunity. Cellular immunity is a key player in this process, but
humoral immunity and autoantibody production also play an
important role.3 Some autoantibodies seem to be protective, but
others are detrimental and associated with accelerated athero-
sclerosis and cardiovascular diseases.4
Among those, we have recently reported the presence of IgG
autoantibodies directed against Apolipoprotein A-1 (anti-ApoA-1
IgG), the major fraction of high-density lipoprotein, as an indepen-
dent predictor of major cardiovascular events, both in rheumatoid
arthritis (RA) patients in primary prevention, and in myocardial
infarction (MI) patients in secondary prevention.5,6 High levels of
anti-ApoA-1 IgG were also reported in patients with systemic
lupus erythematosus and cardiovascular diseases.7 In those clinical
settings, anti-ApoA-1 IgG positivity was significantly associated
with high serum levels of oxidised low-density lipoprotein and
matrix metalloprotease (MMP)-9, two other possible systemic
markers of atherosclerotic plaque vulnerability.5,8–11
Therefore, we investigated the potential involvement of
anti-ApoA-1 IgG as a potential active factor in plaque vulnerability
in humans, mice, and in vitro experiments. Patients without auto-
immune or inflammatory diseases and asymptomatic for ischaemic
stroke, which underwent carotid endarterectomy (CEA) for
severe plaque stenosis, were tested for anti-ApoA-1 IgG. Positive
and negative patients were compared for chemokine and MMP
serum levels and plaque composition. To strengthen these obser-
vations, plaque composition was also assessed in ApoE2/2 mice
treated with goat polyclonal anti-ApoA-1 IgG. Finally, potential
direct pro-atherosclerotic effects of anti-ApoA-1 IgG were
tested in human primary neutrophil, monocyte, and macrophage
functions.
Methods
For additional details, please see the online Supplementary data.
Patients and study design
We conducted a cohort study between March 2008 and April 2010 at
a single hospital (San Martino Hospital) in Genoa (Italy). Patients (n ¼
102), which underwent CEA for severe internal carotid stenosis inci-
dentally diagnosed at US Doppler (.70% luminal narrowing) and
which did not present personal history of ischaemic cerebral symp-
toms, were enrolled in the study. Importantly, magnetic resonance
imaging with diffusion sequences did not show any signs of cerebral
necrosis in all patients enrolled. The degree of luminal narrowing
was determined by repeated Doppler echography and angiographic
confirmation using the criteria of the North American Symptomatic
Carotid Endarterectomy Trial (NASCET).12 The indication for CEA
for asymptomatic patients was based on the recommendations
published by the Asymptomatic Carotid Surgery Trial (ACST) and
the indication for patients’ symptomatic was according to the rec-
ommendations of the European Carotid Surgery Trial (ECST) and
the NASCET.13–15 The day before endarterectomy, blood samples
were obtained by peripheral venipuncture from these patients at
fasting state to collect serum and to perform blood parameters.
Medications reported in Table 1 were not modified in the 2 months
prior to enrolment.
All patients who developed spontaneous cerebral embolism during
30 min preoperatively and during the dissection phase of the operation
(detected by Transcranial Doppler insonation of the middle cerebral
artery) were excluded from the study. Other exclusion criteria were
malignant hypertension, acute coronary artery disease and unstable
angina, any cardiac arrhythmias, congestive heart failure (II, III, and IV
NHYA classes), liver or renal disorders or function abnormalities,
acute and chronic infectious diseases, autoimmune and rheumatic dis-
eases, rheumatoid factors, antinuclear antibody and anti-extractable
nuclear antigen antibody serum positivity, cancer, endocrine diseases,
inflammatory bowel diseases and anti-inflammatory (other than
aspirin) medications, oral anticoagulant treatments, hormone, cytokine,
or growth factor therapies.
The Medical Ethics Committee of San Martino Hospital approved
the study, and participants provided written informed consent. The
study was conducted in compliance with the Declaration of Helsinki.
Animals
Eleven-week-old ApoE2/2 C57Bl/6 mice were submitted to passive
immunization treatment protocol as described in detail in online Sup-
plementary data.
Determination of human autoantibodies
anti-ApoA-1 by ELISA
Anti-ApoA-1 IgG were measured as previously described.5,6 This
method was performed as described in the online Supplementary data.
Detection of inflammatory mediators in
human serum and cell supernatants
This method was performed as described in the online Supplementary
data.
Pro-matrix metalloprotease-9 zymographic
assay
This method was performed as described in the online Supplementary
data.
Human carotid plaque specimen processing
This method was performed as described in the online Supplementary
data.
Immunohistochemistry in human carotid
plaques and mouse aortic sinus
This method was performed as described in detail in the online Sup-
plementary data.
Oil Red O staining for lipid content
This method was performed as described in detail in the online Sup-
plementary data.
Sirius Red staining for collagen content
This method was performed as described in detail in the online Sup-
plementary data.
Real-time RT–PCR
This method was performed as described in detail in the online Sup-
plementary data.
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Human primary neutrophil isolation and
migration assay
This method was performed as described in detail in the online Sup-
plementary data.
Human monocyte isolation and migration
assay
This method was performed as described in detail in the online Sup-
plementary data.
Human primary macrophage differentiation
and culture
This method was performed as described in detail in the online Sup-
plementary data.
Statistical analysis
Patient characteristics were described 1 day before endarterectomy.
Anti-ApoA-1 IgG-positive patients were compared with negative
patients using Pearson’s Chi-square test or Fisher’s exact test, when
appropriate, for the comparison of qualitative variables and Mann–
Whitney non-parametric test (the normality assumption of the vari-
ables’ distribution in both groups was violated) for comparisons of
continuous variables. The comparisons between upstream and down-
stream portions of carotid plaques within anti-ApoA-1 IgG-positive
and -negative groups were performed using Mann–Whitney U-test.
Comparisons between parameters of mouse plaque vulnerability in
anti-ApoA-1 IgG-, isotype control IgG-, and vehicle (PBS)-treated
mice were performed using Mann–Whitney U-test. For continuous
variables, results were expressed as medians [interquartile range
(IQR)].
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Table 1 Clinical characteristics and medications of study population
Characteristics Anti-ApoA-1 IgG negative (n5 82) Anti-ApoA-1 IgG positive (n5 20) P-value
Age, year (IQR) 72 (67–76) 71.5 (66.5–81) 0.10
Males, n (%) 53 (65) 13 (65) 1.00
Systolic blood pressure, mmHg (IQR) 140 (130–150) 145 (130–150) 0.56
Diastolic blood pressure, mmHg (IQR) 80 (80–85) 80 (80–81) 0.92
Waist circumference, cm (IQR) 93.5 86 0.29
Current smoking, n (%) 21 (26) 10 (50) 0.06
Type 2 diabetes, n (%) 13 (16) 2 (10) 0.73
Dyslipidaemia, n (%) 49 (60) 15 (75) 0.30
Hypertension, n (%) 59 (72) 15 (75) 1.00
Chronic CAD, n (%) 14 (17) 6 (30) 0.21
Total WBC, n × 109/L (IQR) 7.1 (6.2–8.1) 8.0 (6.2–9.7) 0.18
Neutrophils, n × 109/L (IQR) 4.5 (3.5–5.2) 5.3 (4–6.8) 0.08
Lymphocytes, n × 109/L (IQR) 1.77 (1.44–2.14) 1.86 (1.18–2.10) 0.60
Monocytes, n × 109/L (IQR) 0.44 (0.37–0.58) 0.46 (0.39–0.60) 0.42
Red blood cells, n × 1012/L (IQR) 4.7 (4.4–5) 4.6 (4.35–4.90) 0.73
Platelet, n × 109/L (IQR) 244 (210–297) 250 (187.5–305) 0.95
Plasma fibrinogen, g/L (IQR) 3.62 (3.14–4.10) 3.73 (3.04–4.53) 0.38
Serum ApoA-1, mg/dL (IQR) 167 (122–217) 208.5 (165–222) 0.08
Serum total-c, mg/dL (IQR) 199 (172–231) 172 (158–198) 0.01
Serum LDL-c, mg/dL (IQR) 117 (90.8–149) 106.5 (88–126) 0.1
Serum HDL-c, mg/dL (IQR) 48 (40–60) 47.5 (42.5–55) 0.88
Serum triglycerides, mg/dL (IQR) 127 (92–175) 102.5 (81.5–138) 0.01
Serum glycaemia, mg/dL (IQR) 98 (89–112) 101 (92–112) 0.59
Serum insulinaemia, mU/L (IQR) 9.5 (6.2–11.6) 8.8 (5.5–17.5) 0.88
Anti-platelets, n (%) aspirin 46 (56) 15 (75) 0.79
Clopidogrel 16 (20) 3 (15) 0.76
Diuretics, n (%) 4 (5) 3 (15) 0.13
ACE inhibitors, n (%) 2 (2) 1 (5) 0.48
ARBs, n (%) 37 (45) 10 (50) 0.89
Beta-blockers, n (%) 24 (29) 5 (25) 0.79
Calcium channel blockers, n (%) 23 (28) 8 (40) 0.42
Statins, n (%) 37 (45) 12 (60) 0.32
Oral anti-diabetics, n (%) 8 (10) 2 (10) 1.00
% Carotid lumen stenosis (IQR) 80 (75–90) 75 (70–80) 0.30
Continuous variables are expressed as median [interquartile range (IQR)].
CAD, coronary artery disease; WBC, white blood cells; total-c, total cholesterol; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; ACE,
angiotensin converting enzyme; ARBs, angiotensin receptor blockers.
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Spearman’s rank correlation coefficients were used to assess corre-
lations between anti-ApoA-1 IgG serum levels and, respectively, intra-
plaque infiltration of vascular and inflammatory cells, collagen and
MMP-9 content, or inflammatory gene mRNA expression (△CT) in
both upstream and downstream regions of carotid atherosclerotic
plaques.
In vitro results were expressed as mean (+SD) (neutrophil and
monocyte chemotaxis assays) and as medians (IQR) (macrophage cul-
tures). One-way ANOVA was used for multiple group comparison,
while unpaired t-test for two-group comparison. Values of P, 0.05
(two-tailed) were considered significant. All analyses were done with
StatisticaTM software (StatSoft, Tulsa, OK, USA) and Analyse-itw
(Analyse-it Software, Leeds, UK) software.
Results
Patient characteristics
Clinical and demographic characteristics, biological parameters as
well as medications in patients with severe internal carotid stenosis
and asymptomatic for ischaemic stroke are described in Table 1.
Serum anti-ApoA-1 IgG were positive in 20 (19.6%) patients,
which are similar to what have been previously observed in
patients with acute coronary syndrome.6,8 There was no significant
difference between patients negative or positive for anti-ApoA-1
IgG in terms of age, sex, and medications. Although most
cardiovascular risk factors were not different between the two
groups, total serum cholesterol and triglycerides were increased
in anti-ApoA-1 IgG-negative patients (respectively, total choles-
terol: 199 vs. 172 mg/dL, P ¼ 0.01 and triglycerides 127 vs.
102.5 mg/dL, P ¼ 0.01).
Systemic levels of inflammatory
biomarkers
No significant differences in serum levels for C-reactive protein,
TNF-a, CCL2, CCL3, and MMP-8 were observed between
anti-ApoA-1 IgG-negative and -positive patients. Although a slight
increase in CCL4 and MMP-9 levels was observed in patients posi-
tive for anti-ApoA-1, differences were not statistically significant
(respectively, CCL4: P ¼ 0.08; MMP-9: P ¼ 0.06, Table 2). Never-
theless, increased gelatinolytic activity for serum pro-MMP-9 was
shown in anti-ApoA-1 IgG positive when compared with negative
patients (Table 2).
Positive serum levels of anti-ApoA-1 IgG
are associated with the increase of
atherosclerotic plaque vulnerability in
humans
We then looked for a difference in plaque vulnerability between
patients positive and negative for serum anti-Apo A-1 IgG. In
upstream portions of carotid plaques, collagen III content was
decreased in anti-ApoA-1 IgG positive when compared with nega-
tive patients (Table 3). Accordingly, intraplaque macrophage and
MMP-9 content were significantly increased in anti-ApoA-1 IgG
positive when compared with negative patients. A slight increase
in MMP-8 mRNA expression was also observed in positive when
compared with negative patients, but the difference was not
statistically significant (P ¼ 0.08). Similar to upstream regions, in
downstream portions of carotid plaques, collagen content was
decreased in anti-ApoA-1 IgG positive when compared with nega-
tive patients. Accordingly, macrophage and MMP-9 content were
increased in anti-ApoA-1 IgG-positive patients. Different from
upstream, in downstream portions, neutrophil intraplaque infiltra-
tion was markedly increased in anti-ApoA-1 IgG positive when
compared with negative patients. No significant differences were
observed in other intraplaque parameters, such as lipid, smooth
muscle cell and lymphocyte content, or inflammatory gene
mRNA expression (Table 3). Circulating anti-ApoA-1 IgG levels
inversely correlated with collagen content (upstream collagen III:
r ¼ 20.35, P ¼ 0.001; downstream total collagen: r ¼ 20.29,
P ¼ 0.008), while positively correlated with macrophage, neutro-
phil, and MMP-9 content in both upstream and downstream por-
tions of carotid plaques (upstream: macrophages: r ¼ 0.28, P ¼
0.009; neutrophils: r ¼ 0.31, P ¼ 0.004; MMP-9: r ¼ 0.40, P ¼
0.001; downstream: macrophages: r ¼ 0.33, P ¼ 0.002; neutrophils:
r ¼ 0.43, P ¼ 0.0001; MMP-9: r ¼ 0.42, P ¼ 0.0001) (Table 4).
Importantly, no significant correlations were observed between
anti-ApoA-1 serum levels and other intraplaque parameters
(Table 4). Taken together, these results indicate that atherosclero-
tic plaque from patients positive for serum anti-Apo A-1 IgG are
more vulnerable than those from anti-Apo A-1 IgG-negative
patients.
Anti-ApoA-1 IgG treatment increases
intraplaque vulnerability in ApoE2/2
mice
To confirm these observations, we determined the impact of
anti-ApoA-1 IgG levels on mouse plaque vulnerability parameters.
We intravenously injected 11-week-old ApoE2/2 mice with goat
polyclonal anti-human ApoA-1 IgG, respective goat IgG controls,
or vehicle (PBS), every 2 weeks over 16 weeks. Mice were fed
before and during treatments with standard chow diet to avoid
the induction of severe hypercholesterolaemia and render lipid
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Table 2 Systemic cardiovascular risk markers
Cardiovascular
markers
Anti-ApoA-1
negative
(n 5 82)
Anti-ApoA-1
positive (n5 20)
P-value
Hs C-reactive
protein, mg/L
1.8 (0.8–5.0) 2.4 (1–3.4) 0.73
TNF-a, pg/mL 15.6 (15.6–19.8) 15.6 (15.6–23.9) 0.47
CCL2, pg/mL 15.6 (15.6–65.3) 27.05 (15.6–151.5) 0.30
CCL3, pg/mL 8.4 (7.7–13.3) 8.7 (7.8–31.9) 0.84
CCL4, pg/mL 30.0 (17.3–52.6) 37.0 (31.3–67.2) 0.08
MMP-9, ng/mL 300 (73–615) 549 (218–1027) 0.06
Pro-MMP-9
activity
20.1 (15.1–28.4) 30.2 (23.8–38.7) 0.009
MMP-8, ng/mL 7.3 (1.3–15.5) 10.4 (6–17.5) 0.15
Data are expressed as median [interquartile range (IQR)].
Hs C-reactive protein, high-sensitivity C-reactive protein; TNF, tumour necrosis
factor; MMP, matrix metalloprotease.
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levels more similar to that detected in human patients.16 At sacri-
fice, the ratio of serum cholesterol sub-fractions and triglycerides
was similar in three mouse groups (Supplementary material
online, Table S1). Atherosclerotic lesion size in thoracoabdominal
aortas was comparable in all groups (lipid deposition on total
aorta surface: PBS: 2.5+0.8%; CTL IgG: 3.6+1.3%; anti-ApoA-1:
3.4+ 0.9%). In aortic roots, atherosclerotic lesion size (as
determined by Oil Red O staining) was increased in anti-ApoA-1
IgG-treated mice when compared with PBS or CTL IgG treatments
(Table 5, Supplementary material online, Figures S1 and S2).
Neutrophil, MMP-8, and MMP-9 contents were also increased in
anti-ApoA-1 IgG-treated mice when compared with control
groups (Table 5, Supplementary material online, Figures S1
and S2). Accordingly, total collagen content was significantly
reduced in anti-ApoA-1 IgG-treated mice when compared with
PBS or CTL IgG treatments (Table 5, Supplementary material
online, Figure S1). Despite a slight increase in intraplaque macro-
phage and lymphocyte infiltration in anti-ApoA-1 IgG-treated
mice, no significant changes were observed between groups
(Table 5, Supplementary material online, Figure S2). The analysis
of mRNA expression of mediators of vulnerability [such as macro-
phage (Cd68 ), neutrophil (neutrophil elastase, Elane ), and Mmp9]
and T helper (Th) lymphocyte polarization in mouse abdominal
aortas, spleen, and lymphnodes partially confirmed several
findings retrieved on histology data (Supplementary material
online, Table S4). These results indicate that anti-ApoA-1 IgG
treatment was associated with increased plaque vulnerability
parameters (i.e. neutrophils and MMPs).
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Table 3 Parameters of intraplaque vulnerability
Carotid intraplaque parameters Anti-ApoA-1 negative (n 5 82) Anti-ApoA-1 positive (n 5 20) P-value
Plaque size, cm 1.7 (1.5–2) 1.5 (1.3–1.9) 0.38
Plaque stenosis, % of lumen 80 (75–90) 75 (70–80) 0.30
Upstream portion
% lipid 5.98 (2.86–9.37) 7.11 (3.31–10.81) 0.42
% total collagen 33.58 (26.15–40.06) 33.29 (25.21–39.24) 0.88
% collagen I 11.54 (9.44–16.9) 13.36 (7.69–15.05) 0.25
% collagen III 13.17 (10.03–17.27) 9.82 (7.55–12.42) 0.005
% of smooth muscle cell-rich area 5.39 (3.16–9.37) 3.53 (2.33–5.85) 0.09
% of macrophage-rich area 4.98 (2.73–9.94) 7.95 (5.59–13.95) 0.02
Lymphocytes/mm2 2.37 (1.12–5.93) 4.03 (1.62–13.67) 0.14
Neutrophils/mm2 2.35 (1.12–6.01) 3.27 (2.18–8.44) 0.19
MMP-8 mRNA, fold increase 1.23 (0.38–3.00) 2.56 (0.66–3.86) 0.08
% MMP-9 2.99 (1.29–5.87) 6.25 (2.40–12.6) 0.02
TNF-a mRNA, fold increase 1.20 (0.54–1.95) 1.22 (0.49–1.94) 0.72
CCL2 mRNA, fold increase 0.93 (0.64–1.39) 1.17 (0.65–1.67) 0.37
CCL3 mRNA, fold increase 0.91 (0.62–1.72) 1.15 (0.79–1.58) 0.71
CCL4 mRNA, fold increase 0.88 (0.55–1.53) 1.02 (0.51–1.31) 0.65
CXCL8 mRNA, fold increase 0.96 (0.52–1.87) 1.32 (0.82–2.00) 0.39
Downstream portion
% lipid 3.45 (1.64–8.37) 4.78 (1.36–10.05) 0.57
% total collagen 20.88 (17.20–23.64) 17.90 (12.82–20.49) 0.01
% collagen I 6.40 (4.27–11.29) 5.45 (2.98–7.04) 0.06
% collagen III 6.63 (4.11–10.28) 4.58 (3.27–5.84) 0.03
% of smooth muscle cell-rich area 2.87 (1.62–4.38) 2.69 (1.69–3.88) 0.69
% of macrophage-rich area 6.88 (2.62–16.12) 11.17 (7.44–18.37) 0.04
Lymphocytes/mm2 2.09 (0.98–5.37) 2.81 (1.24–11.50) 0.34
Neutrophils/mm2 2.98 (0.66–8.51) 9.85 (3.88–15.12) 0.002
MMP-8 mRNA, fold increase 1.13 (0.34–3.25) 1.19 (0.80–2.28) 0.95
% MMP-9 4.77 (1.94–9.66) 19.37 (6.76–25.69) ,0.0001
TNF-a mRNA, fold increase 1.46 (0.78–2.77) 0.96 (0.62–2.06) 0.08
CCL2 mRNA, fold increase 1.37 (0.78–2.05) 1.95 (1.15–2.38) 0.07
CCL3 mRNA, fold increase 1.37 (0.84–2.14) 1.63 (0.58–2.18) 0.87
CCL4 mRNA, fold increase 1.38 (0.89–2.35) 1.75 (0.64–2.45) 0.91
CXCL8 mRNA, fold increase 1.16 (0.54–2.28) 0.91 (0.41–1.71) 0.32
Data are expressed as median [interquartile range (IQR)].
MMP, matrix metalloprotease.
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Treatment with anti-ApoA-1 IgG
increases human neutrophil migration
towards intraplaque chemoattractants
To investigate whether anti-ApoA-1 IgG could be responsible for
neutrophil influx, we tested the effect of anti-ApoA-1 IgG on in
vitro human neutrophil migration. Pre-incubation with goat polyclo-
nal anti-ApoA-1 IgG (at 40 mg/mL) significantly increased neutro-
phil migration towards CXCL8 and TNF-a (both expressed
within atherosclerotic plaques) when compared with CTL
medium or CTL IgG treatments (Table 6). On the contrary, short-
term pre-treatment and co-incubation with goat polyclonal
anti-ApoA-1 IgG (20–40 mg/mL) during chemotaxis assays did
not significantly alter primary human monocyte migration
towards classical chemoattractants (CCL2, CCL3, C-reactive
protein) (Table 7).
Treatment with anti-ApoA-1 IgG induces
the release of CCL2, CXCL8, TNF-a, and
matrix metalloprotease-9 in human
macrophage supernatants
To determine whether anti-ApoA-1 IgG could modulate the pro-
duction of leucocyte chemoattractants and plaque vulnerability
factors, we tested the effect of goat polyclonal anti-ApoA-1 IgG
and respective control on human monocyte-derived macrophages
in vitro. Moreover, to verify that human anti-Apoa-1 IgG had the
same effects as goat anti-ApoA-1 IgG, we purified IgG from
serum of anti-ApoA-1 IgG-positive and -negative patients with
severe carotid stenosis and also tested them on monocyte-derived
macrophages. Goat anti-ApoA-1 IgG significantly increased CCL2,
CXCL8, and TNF-a release when compared with CTL medium or
CTL IgG treatments (Table 8). Similarly, IgG from anti-ApoA-1-
positive patients induced CCL2, CXCL8, and TNF-a production
when compared with treatment with IgG isolated from negative
patients (Table 8). Anti-ApoA-1 IgG significantly increased
release of MMP-9 and gelatinolytic activity of pro-MMP-9 when
compared with treatments with CTL IgG or IgG from negative
patients (Table 8). No effect of anti-ApoA-1 IgG was observed
on MMP-8 secretion in macrophage supernatants at 48 h of incu-
bation (Table 8). The absence of LPS contamination of human iso-
lated IgG, commercial anti-ApoA-1 IgG, and CTL IgG preparations
was confirmed by Limulus assay (0.1 EU/mL for both antibodies,
data not shown).
Discussion
In this study, we demonstrated a positive association between
serum anti-ApoA-1 IgG levels and features of atherosclerotic intra-
plaque vulnerability, such as an increased phagocyte (macrophages
and neutrophils) and MMP-9 content, and a reduced intraplaque
content of collagen in patients with severe but asymptomatic
carotid stenosis. Moreover, most of the associations between
anti-ApoA-1 IgG positivity and vulnerable atherosclerotic plaque
features retrieved in humans (with the exception of intraplaque
macrophages content) were reproduced and confirmed in ApoE
2/2 mice exposed to passive immunization with anti-ApoA-1
IgG. Indeed, even if mice exposed to anti-ApoA-1 IgG did not
develop bigger atherosclerotic lesions, those lesions contained
higher MMP-9, neutrophil content, and lower total collagen
amount, which fulfil some of the possible characteristics of a
prone-to-rupture atherosclerotic lesion.17 In order to explore
the potential mechanisms underlying these observational data in
humans and mice, we investigated in vitro the role of anti-ApoA-1
IgG on both local and systemic processes regulating plaque
vulnerability.
Local inflammation was considered by investigating anti-ApoA-1
IgG effects on human monocyte-derived macrophages, which are
the most abundant inflammatory cell population in atherosclerotic
lesions and have a key role in atherogenesis and plaque vulner-
ability.18 When exposed to human macrophages, goat polyclonal
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Table 4 Spearman rank correlation between
anti-ApoA-1 IgG levels and human intraplaque lipids,
collagen content, cell infiltration, MMP-9, and cytokine
expression in the upstream or downstream regions
Spearman’s correlation
coefficient (r)
P-value
Intraplaque upstream
vs. lipids 0.06 0.562
vs. total collagen 20.12 0.219
vs. collagen I 20.21 0.048
vs. collagen III 20.35 0.001
vs. SMC 20.25 0.017
vs. macrophages 0.28 0.009
vs. lymphocytes 0.11 0.487
vs. neutrophils 0.31 0.004
vs. MMP-9 0.40 0.001
TNF-a mRNA, △CT 20.03 0.820
CCL2 mRNA, △CT 20.07 0.526
CCL3 mRNA, △CT 20.10 0.447
CCL4 mRNA, △CT 20.06 0.586
CXCL8 mRNA, △CT 20.06 0.580
Intraplaque downstream
vs. lipids 0.17 0.191
vs. total collagen 20.29 0.008
vs. collagen I 20.15 0.232
vs. collagen III 20.14 0.245
vs. SMC 20.04 0.725
vs. macrophages 0.33 0.002
vs. lymphocytes 0.13 0.334
vs. neutrophils 0.43 0.0001
vs. MMP-9 0.42 0.0001
TNF-a mRNA, △CT 0.06 0.557
CCL2 mRNA, △CT 20.17 0.194
CCL3 mRNA, △CT 20.13 0.337
CCL4 mRNA, △CT 0.10 0.469
CXCL8 mRNA, △CT 20.04 0.755
SMC, smooth muscle cells.
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anti-ApoA-1 IgG and purified IgG fraction from anti-ApoA-1
IgG-positive patients (preparations devoid of any other common
auto-antibodies) elicited a pro-inflammatory response in terms of
MMP-9 (both activity and protein concentration), CCL2, CXCL8,
and TNF-a. These cytokines play a central role in the recruitment
of inflammatory cells within atherosclerotic plaques.18,19 On the
other hand, MMP-9 selectively degrades gelatin, collagen type IV
and V, thereby weakening the fibrous cap making plaques more
prone to rupture.20 Therefore, anti-ApoA-1 IgG could be directly
involved in plaque vulnerability by promoting the production of
pro-atherosclerotic factors.
Concerning the potential vulnerable activity of serum
anti-ApoA-1 IgG at systemic levels (in the blood stream), we
explored circulating monocyte and neutrophil migration in
response to well-known chemoattractants expressed within
atherosclerotic plaques. As shown by chemotaxis migration
assays, anti-ApoA-1 IgG exposure increased neutrophil migration
towards CXCL8 and TNF-a, but not monocyte migration,
suggesting that anti-ApoA-1 IgG selectively increased circulating
neutrophil locomotion. This effect was partially due to direct che-
mokinetic properties of anti-ApoA-1 IgG, as suggested by the
chequerboard analysis performed in the presence of different con-
centrations of anti-ApoA-1 IgG (data not shown). As neutrophils
have been recently shown to play a crucial role in atherosclerotic
plaque vulnerability, this observation supports the role of
anti-ApoA-1 IgG in this process.19,21
However, the direct effect of anti-ApoA-1 IgG on neutrophil
migration represents a surprising result, for which the mechanism
is still unexplained. Other auto-antibodies, namely anti-neutrophil
cytoplasmic antibodies, have been shown to promote migration
of flowing neutrophils through endothelial cells, presumably by
activating b2-integrin-dependant immobilization.22 On the other
hand, in the human and mouse models of atherosclerosis, the posi-
tive association between anti-ApoA-1 IgG levels and the
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Table 5 Parameters of mouse plaque vulnerability
Parameters Vehicle-treated
mice (n 5 10)
CTL IgG-treated
mice (n 5 14)
Anti-ApoA-1 IgG-treated
mice (n5 9)
Oil Red O, x 103 mm2 198 (171–216) 216 (185–232) 250 (227–297)†
Total collagen, % 41 (32–43) 40 (35–43) 35 (32–40)‡
Macrophage+ area, % 9 (6–11) 10 (6–16) 14 (10–16)§
Lymphocytes/mm2 48.3 (39.5–52.4) 47.1 (29.8–64.3) 49.7 (45.5–59.5)§
Neutrophils/mm2 5 (2–15) 14 (5–19) 20 (14–23)||
MMP-8, % 2 (2–4) 2 (2–4) 8 (4–9)#
MMP-9, % 10 (9–12) 11 (8–16) 21 (16–25)**
Data are expressed as median [interquartile range (IQR)].
MMP, matrix metalloproteinase.
†P, 0.01 vs. CTL IgG-treated mice.
‡P, 0.05 vs. CTL IgG-treated mice.
§P ¼ NS (not significant).
||P, 0.05 vs. CTL IgG-treated mice.
#P, 0.05 vs. CTL IgG-treated mice.
**P, 0.01 vs. CTL IgG-treated mice.
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Table 6 Control (CTL) isotype IgG- and goat anti-ApoA-1 IgG-treated human primary neutrophil migration in
response to classical chemoattractants
Migration assay [polycarbonate, chemotaxis index (C.I.)]
Human neutrophils
Lower well (chemoattractant) Upper well (treated cells)
CTL medium CTL IgG
(20 mg/mL)
CTL IgG
(40 mg/mL)
Anti-apoA-1 IgG
(20 mg/mL)
Anti-ApoA-1 IgG
(40 mg/mL)
CTL medium 1.0+0.0 1.32+0.30 1.14+0.23 0.99+0.19 1.06+0.16
CXCL8 (10 nM) 2.49+0.49* 2.36+0.12 2.28+0.34 2.87+0.98 3.15+0.38†
TNF-a (200 U/mL) 2.42+0.38* 2.06+0.12 2.20+0.58 2.66+0.68 3.1+0.44‡
Data are expressed as mean+ SD (n ¼ 5).
*P, 0.05 vs. CTL medium-treated neutrophil migration towards CTL medium.
†P, 0.01 vs. CTL medium-treated neutrophil migration towards CXCL8.
‡P, 0.05 vs. CTL medium-treated neutrophil migration towards TNF-a.
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intraplaque neutrophil infiltration could be also explained by the
increased release of neutrophilic chemoattractants (CXCL8 and
TNF-a) from infiltrated macrophages (as suggested by our in
vitro experiments with human macrophages incubated in an inflam-
matory microenvironment mimicking atherosclerotic plaque).
To summarize, our human, murine, and in vitro results suggest
that anti-ApoA-1 IgG might be associated with increased athero-
sclerotic plaque vulnerability through two main mechanisms: (i)
the increased intraplaque release of chemoattractants and
MMP-9 and consequent collagen degradation; (ii) the induction
of neutrophil infiltration from the blood stream within athero-
sclerotic plaques.
Those results may have two important clinical impacts for the
management of cardiovascular disease in humans. First, our data
suggest that anti-ApoA-1 IgG assessment could potentially rep-
resent an emerging surrogate circulating marker of carotid athero-
sclerotic plaque vulnerability. Given the actual difficulty to assess
carotid atherosclerotic plaque vulnerability by currently unstandar-
dized methods and resource demanding imaging modalities,23 the
possibility of developing a cheap, standardized, reproducible,
easily available, risk-stratification tool based upon anti-ApoA-1
IgG assessment constitutes a promising approach to better
assess carotid atherosclerosis vulnerability. Second, by demon-
strating in humans and in mice a direct negative effect of
anti-ApoA-1 IgG on atherosclerotic plaque stabilization, it is
likely that anti-ApoA-1 IgG could be considered an active factor
increasing cardiovascular vulnerability. Given the recent demon-
stration of passive immunization approach as an emergent
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Table 8 Secretion of neutrophil and monocyte chemoattractants, as well as MMP-8 and MMP-9 from human primary
macrophages
Cell culture assay
Mediator
released
Stimulation
CTL
medium
LPS (1 ng/mL) CTL IgG
(40 mg/mL)
Anti-ApoA-1 IgG
(40 mg/mL)
anti-ApoA-1
IgG-negative
patients
anti-ApoA-1
IgG-positive
patients
CCL2, pg/mL 7 (5–11) 260* (233–2876) 6.9 (4.6–9.5) 291† (225–1047) 10.8 (8–42.9) 173.7§ (134.7–264.7)
CXCL8, pg/
mL
131 (62–180) 7158* (6591–16840) 51 (73–228) 4189† (4181–11654) 209 (160–313) 1327§ (788–2274)
TNF-a, pg/mL BDL 320* (225–456) BDL 74† (25–106) BDL 33§ (12.1–52)
MMP-8, pg/
mL
95 (57–168) 326* (54–3635) 1 (1–77) 14.8‡ (1–173) 71 (34–3192) 139|| (43–28359)
MMP-9, ng/mL 4.2 (0.4–62) 26* (14–32) 8.7 (4–13) 59† (45–83) 8.4 (3.7–15.3) 40§ (16.6–59)
Pro-MMP-9
activity,
ng/mL
16 (14–18) 50* (37–61) 21 (16–23) 32‡ (27–42) 18 (16–21) 33§ (25–40)
Data are expressed as median and (IQR) (n ¼ 7). BDL, below the detection limit of the assay. For statistical analysis, the lower detection limit value was used.
*P, 0.05 vs. control medium.
†P, 0.05 vs. control IgG.
‡P: NS (not significant) vs. control IgG.
§P, 0.005 vs. anti-ApoA-1 IgG-negative patients.
||P ¼ NS (not significant) vs. anti-ApoA-1 IgG negative patients.
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Table 7 Control (CTL) isotype IgG- and goat anti-ApoA-1 IgG-treated human primary monocyte migration in
response to classical chemoattractants
Migration assay [polycarbonate, chemotaxis index (C.I.)]
Lower well (chemoattractant) Upper well (treated cells)
CTL medium CTL IgG
(20 mg/mL)
CTL IgG
(40 mg/mL)
Anti-ApoA-1 IgG
(20 mg/mL)
Anti-ApoA-1 IgG
(40 mg/mL)
CTL medium 1.0+0.0 0.92+0.06 0.98+0.21 1.01+0.08 0.94+0.22
CCL2 (10 nM) 2.19+0.38 2.19+0.52 2.26+0.18 2.52+0.45 2.62+0.41
CCL3 (10 nM) 2.08+0.38 2.19+0.50 2.17+0.39 2.60+0.76 2.62+0.41
C-reactive protein (40 mg/mL) 2.13+0.56 2.34+0.62 2.11+0.25 2.39+0.42 2.46+0.26
Data are expressed as mean+ SD (n ¼ 6). No comparisons between groups are statistically significant.
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therapeutic modality to treat some atherosclerotic diseases in
humans and mice, we can hypothesize that intravenous adminis-
tration of immunoglobulin (IVIG) or other more specific-targeted
antibodies-based therapies could neutralize the deleterious effect
of anti-ApoA-1 IgG on atherosclerotic plaque stability.24 This
potential approach was recently tested in vitro on cardiomyocytes,
showing that treatment with IVIG abrogated the chronotropic
effects of anti-ApoA-1 IgG.6
The limitation of the herein study is the relative limited sample
size of carotid human specimens (n ¼ 102) due to the application
of very stringent exclusion criteria to avoid any potential confoun-
ders, related to potential inflammatory and autoimmune
co-morbidities, as well as anti-inflammatory medications. Thus, it
may be possible that little changes in intraplaque (inflammatory
gene and MMP-8 mRNA expression) and systemic (CCL4,
MMP-9) parameters failed to reach statistical significance. Never-
theless, this limitation was the trade-off to obtain a pure model
of human atherosclerosis in primary prevention, which also consti-
tutes strength of this cohort. Whether our results apply also to
unselected patients with carotid atherosclerosis remain to be
demonstrated. Also, anti-ApoA-1 IgG positive differed from nega-
tive patients only for total serum cholesterol and triglyceride levels
(both increased in anti-ApoA-1 IgG-negative patients). Given the
role of circulating lipids as a well-known cardiovascular risk
factor, this aspect suggests anti-ApoA-1 IgG-negative patients to
potentially be at increased cardiovascular risk when compared
with positive patients. However, as levels of total cholesterol and
triglycerides were not markedly elevated in both groups, we can
assume that these alterations in lipid profile did not reasonably
induce any remarkable pro-atherosclerotic effects in the study
population.25 Finally, it must be reminded that there is currently
no strict consensus about the exact definition of vulnerable
plaque in humans, and about the model system that is best
suited to investigate plaque rupture in mice.26 The situation is
further complicated by the fact that vulnerability criteria used in
humans (mostly histological) might not apply to mice.23 In this
context, observing such a similarity between human and mice
results undoubtedly constitutes another strength of the herein
study. On the other hand, being focused on assessing the relevance
of anti-ApoA-1 IgG in humans in vitro, we performed our in vitro
experiments only on human primary immunocompetent cells,
and not mice-derived neutrophils or macrophages. Therefore,
we cannot formally extrapolate our in vitro results obtained on
human cells to mice-derived inflammatory cells. This approach
limited the direct relevance of anti-ApoA-1 IgG pro-inflammatory
activities to humans instead of the animal model. Another limit-
ation resides in the fact that we did not explore the potential inter-
ference of anti-ApoA-1 IgG with more classical ApoA-1-related
properties, such as reverse cholesterol transport, anti-
inflammatory, or anti-oxidant activities, which in turn might con-
tribute to cardiovascular vulnerability.27
In conclusion, anti-ApoA-1 IgG increased cardiovascular vulner-
ability in humans and ApoE2/2 mice. Intraplaque markers of vul-
nerability (such as MMPs, macrophage, and neutrophil content)
were increased in anti-ApoA-1 IgG-positive patients and by
anti-ApoA-1 IgG treatment in mice. Accordingly, anti-ApoA-1
IgG was inversely correlated with intraplaque collagen content.
Furthermore, in vitro anti-ApoA-1 IgG increased neutrophil
migration in response to classical neutrophilic chemoattractants,
expressed in atherosclerotic plaques. In addition, anti-ApoA-1
IgG stimulation was associated with the promotion of the
release of monocyte and neutrophil chemoattractants, as well as
MMP-9 by human macrophage. These results suggest that
anti-ApoA-1 IgG might be associated with atherosclerotic plaque
vulnerability. This could explain the poor cardiovascular prognosis
observed in anti-ApoA-1-positive patients with MI or RA,5,6 but
remains to be demonstrated in larger prospective clinical studies.
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